REG - Futura Medical PLC - Block Listing Six Monthly Return

Futura MedicalAnnouncement

30/11/2023 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231130:nRSd2671Va&default-theme=true

RNS Number : 2671V  Futura Medical PLC  30 November 2023

Block Listing Six Monthly Return

30 November 2023

Futura Medical plc (AIM: FUM), the pharmaceutical company developing
innovative sexual health products, makes the following update on its block
listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for
Companies. All figures relate to options over Ordinary Shares of 0.2 pence
each (Ordinary Shares).

 

 Name of applicant:                                                                Futura Medical Plc
 Name of scheme(s):                                                                Unapproved Share Option Scheme

                                                                                   Unapproved Share Incentive Scheme

                                                                                   EMI Share Option Scheme

                                                                                   LTIP Scheme
 Period of return:                        From:                                    1 June 2023         To:                 30 November 2023
 Balance of unallotted securities under scheme(s) from previous return:            12,526,721
 Plus:  The amount by which the block scheme(s) has been increased since the       LTIP: 10,590,675
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period:        USOS: nil

                                                                                   EMI: 756,000

                                                                                   LTIP: 1,578,731

 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        20,782,665
 Number and class of securities originally admitted and the date of admission      USOS Total: 3,882,912

                                                                                   814,424 25 May 2011

                                                                                   1,202,280             8 October 2013

                                                                                   1,466,208             25 May 2017

                                                                                   400,000 30 May 2018

                                                                                   USIS Total: 425,000

                                                                                   425,000 30 November 2018

                                                                                   EMI Total: 8,112,088

                                                                                   1,520,576             25 May 2011

                                                                                   1,467,720             8 October 2013

                                                                                   1,893,792             25 May 2017

                                                                                   790,000 30 May 2018

                                                                                   1,340,000             30 November 2018

                                                                                   1,100,000           2 February 2023

                                                                                   LTIP Total:  15,035,617

                                                                                   4,444,942            2 February 2023

                                                                                   10,590,675          3 November 2023

 

For further information please contact:

 

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

 

Nominated Adviser and Sole Broker:

 

Liberum

Phil Walker / Ben Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Nick Bastin/ Jonathan Edwards/ Elena Bates

Email: futuramedical@optimumcomms.com (mailto:futuramedical@optimumcomms.com)

Tel: +44 (0) 203 882 9621

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Development and commercialisation
strategies are designed to maximise product differentiation and value creation
whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a novel treatment for
erectile dysfunction (ED) through a unique evaporative mode of action. Futura
has conducted two Phase 3 studies using MED3000 in ED; FM57 study which
enabled Futura to be granted a CE Mark in 2021 and FM71 which enabled Futura
to be granted US marketing authorisation. Both studies demonstrated that
MED3000 presents an effective clinically proven treatment for ED with a rapid
speed of onset and a favourable benefit versus risk profile ideally suited for
an 'Over the Counter' classification.

Eroxon® is FDA approved in the US, CE marked in Europe and UKCA marked in
the UK as a clinically proven topical treatment for adult men with
erectile dysfunction under the brand Eroxon® with a key claim of "Helps you
get an erection within 10 minutes". Eroxon® is the agreed brand name in
certain regions such as the EU whereas MED3000 continues to be the internal
code name used by the Company and also in reference to countries where
regulatory approval or commercial distribution agreements have not yet been
achieved. www.eroxon.com (http://www.eroxon.com/)

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRURVSROUUAOAA